Testing begins on drug treatment for hearing loss and tinnitus

LONDON–Autifony Therapeutics, a British startup biotech company, has launched a Phase 1 trial of an experimental drug, AUT00063, that is designed to treat age-related hearing loss and tinnitus by targeting deficits in auditory processing in the brain that are believed to cause these problems. Charles Large, PhD, co-founder and chief scientific officer of Autifony, noted, “We…

Read More